Quarterly ResultMay 7, 2026, 04:24 PM
Charles River Labs Q1 Net Loss $(14.8)M; $507M NHP Acquisition; $118M Divestment Loss
AI Summary
Charles River Laboratories International, Inc. reported a net loss of $14.8 million, or $(0.30) diluted EPS, for the first quarter of 2026, a significant decline from a net income of $25.9 million in the prior year. Total revenue saw a modest increase to $995.8 million. The company completed the acquisition of a Cambodian NHP supplier for $507.3 million and PathoQuest SAS, while also divesting its CDMO and Cell Solutions businesses, which resulted in a pre-tax loss of $118.0 million. Additionally, an agreement to sell certain European Discovery Services businesses for $145.0 million is in progress.
Key Highlights
- Completed acquisition of Cambodian NHP Supplier for $507.3 million on January 14, 2026.
- Completed divestment of CDMO and Cell Solutions businesses, incurring a $118.0 million pre-tax loss.
- Agreed to sell certain European Discovery Services businesses for $145.0 million.
- Reported Q1 2026 net loss of $14.8 million, down from $25.9 million net income in Q1 2025.
- Diluted EPS was $(0.30) in Q1 2026, compared to $0.50 in Q1 2025.
- Total revenue increased 1.2% to $995.8 million in Q1 2026 from $984.2 million in Q1 2025.
- Manufacturing segment operating income improved to $46.8 million from a $(8.6) million loss year-over-year.
- Net cash provided by operating activities decreased to $41.1 million from $171.7 million.